“I would imagine that that will increase and grow over time.”

In context

“es from Mohit Bansal from Wells Fargo. Please go ahead. Your line is open. Mohit Bansal: Great. Thank you very much for taking my question and congrats on all the good progress here. Maybe like, just again, the question on PCSK nine and at this point. So Murdo, can you please remind us what percentage of your prescriptions are coming from primary care at this point? And with the Vesilius data, like how do you see the primary case segment of the market evolving over time? Thank you. Murdo Gordon: Yeah, thanks Mohit. I put a number out before the Vesalius data promotion started where roughly 40% of our prescriptions were coming from patients who were considered primary prevention, patients who have not yet had an event. Where physicians were looking to lower those patients' LDL cholesterol. I would imagine that that will increase and grow over time. What we're seeing is equal interest quite frankly from cardiologists who are excited by the Vesalius data and the consistency of both the primary endpoint, the secondary endpoint the MI subgroup, quite frankly the overall incidence of death in the trial was also something that attracted attention. From specialists. So the cardiology group has seen this as an affirmation of what they were already doing and being aggressive in treating LDL cholesterol. And primary care physicians, as I mentioned, are much more intent and aligned to adding Rupatha to the optimized statin therapy that most patients are on. As for how much we don't give product specific guidance. But hopefully you can tell I am extremely excited about the momentum that we have on Repatha right now. I'm really pleased with the”